Day 2 :
Time : 10:00-10:35
Dr. Zhinan Xia is a recognized leader in antibody technologies and therapeutics. He earned his Ph.D. degree in protein engineering from the College of Pharmacy at the University of Kentucky. He also completed an M.S. degree in drug design from the China Pharmaceutical University, Nanjing, China, and a B.S. degree in medicinal chemistry from Nanjing College of Pharmacy, Nanjing, China.
Rapidly discover and optimize therapeutic mAb is the key factor to success in a very competitive fast changing global pharmaceutical market place. We have developed a very rapid approach that allows you to discover novel therapeutic m Ab lead molecule in a few months. Here is what you need: a good humanized transgenic mice, phage/yeast display and NGS capability. This talk will demonstrate how we obtain a mAb drug development candidate in less than 4 months from mice immunization, phage display/NGS to pm affinity lead molecule identification
Coffee break 10:35-10:50@Foyer
Merck Research Laboratory, Kenilworth, USA
Keynote: Cell culture kinetics and automation
Time : 10:50-11:25
Yung shyeng Tsao received his PhD from the University of Tennessee, specialized in Liposome and Membrane Technologies. He was a Post-doctoral Fellow in New York University, specialized in Membrane Trafficking and Protein Secretion Mechanisms. He joined Schering-Plough Research Institute/Merck in 1988 and developed cell lines for gene therapy and recombinant protein production. He has published in the area of protein isolation and characterization, membrane biophysics and fusion mechanisms, liposome drug targeting, membrane trafficking, protein secretion and degradation mechanisms, animal cell culture media, serum-free virus production, aggregated cell monitoring, cell growth-protein productivity-metabolic modeling, cell culture miniaturization and automation, and transcriptome and integrative pathway analysis.
Mammalian cell culture automation relies on timely detection of cultural parameters, such as cell densities, metabolic concentrations as well as waste build-up, and a reliable algorithm for timely intervention to sustain cellular well-being and desired productivity. The conventional approach for calculating cell growth and metabolic rates is mostly time-based. However, if cell densities, metabolite concentrations and product titer are plotted against IVCC (Integral of Viable Cell Count) then the slopes would show their specific rates. The IVCC conversion can not only provide direct visual cues for the investigators but is also more accurate than the time-based analysis for specific rate computation since it is not affected by the fluctuations in cell viability during the cell culture batch. In this presentation, we will show how parameters such as glucose, lactate, glutamine and glutamate can be used to determine cell densities, viability and cell growth rate without counting cells, once the correlation for the cell line is established. We will also show that the IVCC approach can demonstrate distinct phase changes for cell growth, death and product formation which correspond to different metabolic phase changes for 12 individual CHO clones expressing the same therapeutic antibody investigated. In addition, the efficiency of cell making is shown to determine the maximal cell density and the duration of cell culture of the fed-batches. In conclusion, IVCC approach can be a key for cell culture automation which requires simplicity, sensitivity, accuracy and predictability.
The University of Waikato, Waikato, New Zealand
Time : 11:25-12:00
Dr. Aydin Berenjian is a lecturer at the University of Waikato (New Zealand). Aydin has BE, ME and PhD in biochemical engineering. After graduation from the university of Sydney (Australia), Aydin began his career as a postdoctoral research fellow and later on, in 2014 he became a lead researcher in the field of bioprocess engineering at the University of Waikato. Aydin’s main research interests are: Fermentation technology including upstream and downstream processing; Biofilm technology; Kinetics, modelling and optimization of bioprocesses; drug biosynthesis and Functional foods. He serves as the editor of Molecular Biotechnology (Springer Science, Germany) and Associate Editor of American Journal of Biochemistry and Biotechnology (Science Publication, USA). Aydin has published more than 50 peer-reviewed articles, and renowned 2 international patents. He has also won several prestigious awards including IChemE and WCECS Research Awards.
The Vitamin K series, particularly menaquinone, have been attracting research attention, due to the potential in reducing both osteoporosis and cardiovascular diseases. To date I have investigated the various biotechnological approaches for the production of menaquinone, including types of fermentations, extraction and recovery to significantly reduce the production price. Breakthroughs in up-streaming and down-streaming the production process for menaquinone will be discussed. Recommendations will be given for areas of future research in order to improve the production process for menaquinone and reduce costs.